Table 3 Baseline patient characteristics
From: Real-life cost-effectiveness of benralizumab in patients with severe asthma
Parameter | n = 44 |
|---|---|
Age, years (mean ± SD) | 53.8 ± 10.4 |
Women, n (%) | 35 (79.5) |
BMI (mean ± SD) | 28.7 ± 6 |
Smoking | |
Never smoker, n (%) | 23 (52.3) |
Ex-smoker, n (%) | 21 (47.7) |
Former smoker, n (%) | 0 (0) |
Age at diagnosis, years (mean ± SD) | 28.95 ± 12.4 |
Dyspnoea | |
Degree 0–2, n (%) | 22 (50) |
Degree 3–4, n (%) | 22 (50) |
Atopy, n (%) | 15 (34.1) |
Corticosteroid-dependent, n (%) | 18 (40.9) |
Nasal polyps, n (%) | 14 (31.8) |
AERD, n (%) | 6 (13.6) |
ACT (mean ± SD) | 13.7 ± 4 |
ED visits in the previous year, (mean ± SD) | 4.1 ± 2.6 |
Number of severe exacerbations in the previous year, (mean ± SD) | 5.50 ± 2.63 |
Number of asthma admissions in the previous year, (mean ± SD) | 0.59 (1.1) |
Courses of OCS in the previous year, (mean ± SD) | 5.8 ± 3.3 |
Oral prednisone (or equivalent) dose, mg/day (mean ± SD) | 19.3 ± 8.8 |
Inhaled budesonide (or equivalent) dose, μg/day (mean ± SD) | 993 ± 485 |
Post-BD FEV1, mL (mean ± SD) | 1455.8 ± 495.7 |
Post-BD FEV1, % (mean ± SD) | 65.7 ± 14.1 |
FeNO, ppb (mean ± SD) | 56.6 ± 26.2 |
Blood eosinophil count, cells/μL (mean ± SD) | 718.3 ± 287.5 |
IgE, IU/mL (mean ± SD) | 223.6 ± 394.9 |
Prior treatment with a biologic agent, n (%) | 23 (52.3) |
Omalizumab, n (%) | 16 (36.4) |
Mepolizumab, n (%) | 5 (11.4) |
Omalizumab + Mepolizumab, n (%) | 2 (4.5) |
Time with previous biological treatment, months (mean ± SD) | 20.7 ± 23.3 |